Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 Grams
Price: Negotiable
Packaging Details: 1~10 KG Aluminum Foil Bag, 25KG/drum
Delivery Time: 1-3 working day
Payment Terms: L/C, L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Storage: |
Store In A Cool, Dry Place |
Molecular Formula: |
C13H19N3O7 |
Shelf Life: |
2 YEARS |
Molecular Weight: |
329.31 |
Product Name: |
Molnupiravir (EIDD-2801) |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Storage: |
Store In A Cool, Dry Place |
Molecular Formula: |
C13H19N3O7 |
Shelf Life: |
2 YEARS |
Molecular Weight: |
329.31 |
Product Name: |
Molnupiravir (EIDD-2801) |
Cas: |
2349386-89-4 |
Grade: |
Pharmaceutcial Grade |
Test: |
HPLC |
Molnupiravir powder is the powdered form of the antiviral drug Molnupiravir (also known as EIDD-2801). Molnupiravir is chemically known as β-D-N^4-hydroxycytidine. It is a prodrug, meaning it is metabolized in the body to its active form, N^4-hydroxycytidine triphosphate, which then inhibits viral RNA polymerase, preventing viral replication.
Molnupiravir has shown efficacy against various RNA viruses in preclinical studies, including influenza A and B viruses, respiratory syncytial virus (RSV), chikungunya virus, Venezuelan equine encephalitis virus, and coronaviruses like SARS-CoV-2.
Technical Parameters | Nootropics Powder |
---|---|
Product Name | Molnupiravir (EIDD-2801) |
Grade Standard | Pharmaceutical Grade |
Assay | 99.9% |
Apperance | White Powder |
Service | Worldwide |
Shelf Life | 2 YEARS |
Molecular Formula | C13H19N3O7 |
Test | HPLC |
Storage | Store In A Cool, Dry Place |
1. COVID-19 Treatment: Molnupiravir has been investigated as a potential treatment for COVID-19. Clinical trials have shown that it may reduce the viral load and alleviate symptoms in patients with mild to moderate COVID-19. It could be particularly useful in early-stage infections to prevent disease progression.
2. Treatment of Viral Infections: Molnupiravir has shown promise in treating a variety of RNA virus infections, including influenza viruses, coronaviruses (such as SARS-CoV-2), respiratory syncytial virus (RSV), and others. Its broad-spectrum antiviral activity makes it a candidate for treating a range of viral illnesses.
3. Prevention of Viral Transmission: Molnupiravir could be used as a prophylactic treatment to prevent viral transmission in individuals at high risk of exposure to certain viruses, such as healthcare workers or close contacts of infected individuals.